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Mutations arising n viuvo in recorder genes ofhuman blood cells provide biomarkers for mlecular epidemiology by serv-
ing as surrogates for cancer-causing genetic changes. Current markers include mutations ofthe glycophorin-A (GPA) or
hemoglobin (Hb) genes, nmasured in red blood cells, or mutations ofthe hypoxanthine-guanine phosphoribosyltransferase
(hp,t) or EHLA genes, measred in T4ymphocytes. Mean mutant frequencies (variant frequencies) for normal young adults
are approximately: Hb (4 x10`) < hprt (5 x 10') = GPA (10 x 10') <HLA (30 x 10 . Mutenposed individuals
show decided elevations. Molecular mutational spectra are also being defined. For the hpit marker system, about 15%
ofbackground mutatin aregrossr al alterations ofthehptgene (e.g., ddetion); theremainderarepoint mutations
(e.g., base substitutions or frameshifts). Ionizing rdiations result in doserelated increases in total gene deletions. Large
deletions may encompass several megabases as shown by co-deletions oflinked markers. Possible hpit spectra for defin-
ing radiationand chemical exposures are being sought. In addition to their responsveness toenvironmental utagens/car-
cinogens, three additional fmdings suggest that the in vivo recorder mutations are relevant in vivo surrogates for cancer
mutations. First, a large fraction ofGPA and HLA mutations show exchanges due to homologous recombination, an im-
portant mutational event in cancer. Second, hprt mutations arise preferentially in dividing T-cells, which can accumulate
additional mutations in the same clone, reminiscent ofthe multiple hits required in the evolution ofmalignancy. Finally,
fetal hpit mutations frequently have characteristic deletions ofhpltexons 2 and 3, which appear to be mediated by the VDJ
recombinase that rearranges the T-cell receptor genes during thymic ontogeny. Illegitimate events such as these also ap-
pear to occur in human leukemias.
Introduction
Molecular epidemiology is an attempt to combine the disease
relevance oftraditional epidemiology with the use ofbiomarkers
to overcome limitations in studying diseases that are infrequent
or have long incubation periods. Biomarkers measure the in vivo
effects of deleterious environmental agents and may even serve
as surrogates for disease. However, interpretation of human
studies is dependent on the biomarker employed. Does it sen-
sitively detect exposures? Is there any specificity? Does the
biomarker detect only exposure or does it reveal in vivo toxic ef-
fects that, while not disease effects, help to predict them?
Answers, ofcourse, require an understanding of the biology of
the biomarkers.
Some human cancers are undoubtedly caused, at least in part,
by genotoxic carcinogens. Human exposures to these agents can
be monitored by biomarkers of chromosome or gene level
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damage, or through direct assessments of DNA damage,
chemical adduction, or repair. This review will consider a par-
ticular subset of these, i.e., gene level damage. Specifically, we
will focus on the measurement and analysis of somatic cell gene
mutations arising in vivo in human blood cells. Although all of
the assays for human monitoring will be considered, the em-
phasis will be on in vivo hypoxanthine-guanine phosphori-
bosyltransferase (hprt) mutations in T-lymphocytes.
Cells Used for Studies of Current
Biomarkers of in Vivo Somatic Cell
Mutations in Humans
At present, mutations are scored as mutant cells in peripheral
blood, i.e., red blood cells (RBCs) or T-lymphocytes (T-cells)
(Table 1). However, the mutations giving rise to these mutants
arise in progenitor cells. For the RBC assays, mutations arise in
multipotent stem cells or in somewhat differentiated he-
matopoietic precursor cells in the bone marrow. Continual pro-
liferation and differentiation ofthese mutant progenitors produce
the peripheral blood RBCs scored in the assays. For the T-cell
assays, mutations in adults arise in differentiated, mature T-cells
(1), probably in lymph nodes or other body tissues. Although
fully differentiated, these cells retain the capacity for limited
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Table 1. Characteristics of cells used in assays for human in ivo
somatic mutations.
Mutant Target cells for Body compartment Metabolic competence
cells mutation for mutation of target cell
RBC Multipotent stem Bone marrow Probable, also, stem
cell, differenti- cell surroundedby
ated precursor competent
cell macrophages
T-cell Post-thymic Blood Competent (partial?)
(adults) Most tissues Proximity to other
Prethymic (fetus) Bone marrow tissues
Thymus (?)
but repetitive cell division after stimulation in vivo (usually by
antigen), providing expanded clones derived from original pro-
genitors. Mutant T-cells deriving from mutations in expanding
clones make up a greater or lesser fraction of these clones,
depending on when they occur during clonal expansion. In the
fetus, however, and presumably in children and adolescents,
mutations may arise in pre- or intrathymic pre-T-cells. The
prethymic progenitors ofT-cells may even be bone marrow stem
cells, in which case the kinetics of appearance and persistence
of T-cell mutants in peripheral blood will be similar to what is
seen for RBC mutants.
The differentiation stage of mutational target cells relative to
the mutants scored in an assay determines some characteristics
of that assay's results [reviewed in Albertini et al. (2)]. For ex-
ample, mutations arising in stem cells continuously produce mu-
tant progeny. Therefore, a characteristic of stem cell mutations
for human monitoring is memory, i.e., mutations arising in the
distant past can be detected. Costs ofmemory, however, include
variability, determined in part by the number of stem cells pro-
ducing the population ofmature cells sampled at any given time,
and loss of temporal relationships between induced mutational
events and the detection ofmutants in peripheral blood. In con-
trast, mutations arising in differentiated T-cells are more closely
related in time to the presence of mutant cells in the peripheral
blood, especially ifthere is a finite life span ofmutants. The cost,
of course, is memory.
Mature RBCs have lost their nucleus. There is, therefore, no
possibility for molecular studies to define molecular spectra of
mutations. The term "variants" acknowledges this. T-cells, how-
ever, can be propagated in vitro and studied at the molecular
level. Also, the T-cell receptor (TcR) genes, which rearrange
during thymic differentiation of individual T-cells, may be
analyzed in these cells relative to mutations (1). This allows deci-
sions to be made regarding the in vivo independence ofdifferent
mutant isolates and the differentiation stage in vivo when the
mutation occurred.
There is probably metabolic competency for the target cells for
both the hematopoietic and T-cell mutations. Hematopoietic
precursor cells are surrounded by metabolically active macro-
phages in the bone marrow. Mature T-cells are partially
metabolically competent and circulate through all ofthe tissues,
where they are probably exposed to mutagenic metabolites.






































HbA (normal) - HbS (sickle cell Hb) mutations are
detected by fluorescent anti-HbS antibody treatment
of fixed RBCs on slides. The rare fluorescent cells in
a HbA/HbA homozygous individual are scored by an
image analyzer (52).
Anti-M and anti-N antibodies, labeled with green and
red fluorophors, respectively, are used to double label
wild-type (nonmutant) RBCs from M/N heterozygous
individuals. A single or dual beamcell sorterdetects the
loss ofeither antigen (MO or NO) (hemizygous) or double
expression oftheother (MM or NN) (homozygous). The
first is due to simple allele loss; the second is due to
somatic recombination or gene conversion (54).
The short-term assay measures first-round DNA syn-
thesis of stimulated T-cells in vtro in6-thioguanine (TG)
by either autoradiography or BrdU incorporation.
Labeled cells presumably have undergone in vwvo hprt
mutation (19).
For the cloning assay, direct cloning of T-cells is per-
formed with or without 6-TG in the presence of T-cell
growth factor and feeder cells (56-58).
HLA mutants are detected by direct cloning of T- cells
after their treatment with anti-HLA monoclonal an-
tibodies to eliminate wild-type cells (60).
End Range of
point mean values
Vf 4 X o-a
(17)









Mf 30 x 10-6
(6)
Abbreviations: Vf, variant frequency; Mf, mutant frequency.
aSingle study.
bHemizygous mutant = single loss (see text).
CHomozygous mutant = loss with gain of homologous allele (see text).
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Assays Used for Studies of Current
Biomarkers of in Vivo Somatic Cell
Mutations in Humans
Four assays are currently available for measuring in vivo
somatic cell gene mutations in humans (Table 2). An understan-
ding of the biology of each assay is important for its interpreta-
tion, especially for comparing results across assays. The muta-
tional target sizes of the four genes studied in these assays differ.
The Hb gene is 2 kb in length; however, the functional target
size for the mutation currently scored isa single base change. The
glycophorin A (GPA) and hprt genes are approximately equal in
size; however, for GPA, the immunological methods used in the
assay define target size by the antibody used and the protein struc-
tures required for recognition, whereas for hprt, chemical selec-
tion for mutants requires loss of catalytic activity of the HPRI en-
zyme, which may not occur following all possible mutations of
the gene. For HLA, although this is, in principle, another large
target gene, the immunological methods used for mutant detec-
tion make it difficult to define target size.
Autosomal genes (hemoglobin [Hb], GPA, HLA) allow for the
detection of interhomologous chromosome mutational events,
such as somatic recombination and gene conversion, in addition
to the more commonly considered mutational events, thus pro-
viding surrogates for events that may be important in the genesis
of cancer. In contrast, the hprt gene is on the X-chromosome,
which is either actually or functionally hemizygous in all mam-
malian cells; therefore, interhomologous chromosome muta-
tional events cannot occur at hprt. Results, to be considered
below, should be interpreted in light of these biological char-
acteristics.
Quantitative Aspects
Studies from several laboratories have reported background
mutant or variant frequency values (Mf; Vf) for normal adults
(Table 2). Background mutations are not synonymous with spon-
taneous mutations because the causes are not known. However,
the terms are often used interchangeably. In summary, the
relative order ofbackground Mf(Vf) values from normal adults
for the several markers is: Hb > hprt = GPA > HLA. Age-
related increases in these values have been reported for GPA,
hprt, and HLA (3-7).
Qualitative (Molecular) Aspects
T-cells can be recovered from cloning assays and propagated
in vitro into populations of sufficient size for molecular analyses.
Although this has been accomplished for both hprt and HLA
mutations, the largest database at present is for hprt.
hprt. There has been quite good aggreement among labora-
tories that approximately 15% ofhprt mutations in normal adults
result from gross structural alterations (2,8-11). These include
deletions, insertions, and rearrangements visible on Southern
blots. The breakpoints ofthe alterations are distributed randomly
within the gene, with no "hot spot" thus far identified (2). Total
deletions of hprt may show co-deletion of linked anonymous
markers, which map several centiMorgans distant in both 5' and
3' directions, indicating that deletions can be quite large (12).
The remaining 85% ofthe background in vivo hprt mutations
in adults consist of point mutations. Because of the importance
of hprt as a genetic target, a repository has been established to
collate information on in vivo and in vitro mutations in human
cells developed in all laboratories engaged in such studies
worldwide (13). More than 700 such mutants have been seq-
uenced to date. The mutations characterized include more than
200 somatic mutations derived from normals, smokers,
chemotherapy patients, and patients with the DNA repair
disorders xeroderma pigmentosum and ataxia telangiectasia.
Fifty-seven germinal hprt mutations (Lesch-Nyhan syndrome)
also have been characterized. In addition, several hundred hprt
mutations generated in vitro by agents including ethyl nitrosourea
methyl-N-nitroguanidine, formaldehyde, ICR-191, cyanoethylene
oxide, cisplatin, benzo[alpyrene diol epoxide, and UV light have
been sequenced. The data collected to date suggest that hprt is
sensitive to all mutation types, including base pair substitutions,
frameshifts, and deletions of various sizes. A total of 227 dif-
ferent base substitutions have been observed at 172 of the 657
bases of the coding region. Of these, approximately 85% were
missense mutations, 13% nonsense mutations, and 2% did not
lead to any amino acid change. (The latter class of mutations may
express phenotypically due to codon usage problems or due to
decreased stability of the resulting hprt mRNA.) Every class of
base substitution has been observed at similar frequencies and
was distributed throughout the coding region in all nine exons of
hprt. Thirty-eight frameshifts (25 -1, 13 +1) involving both GC
and AT base pairs have been observed. In general, frameshift
mutations occurred at or adjacent to sequences containing two
or more consecutive identical bases. Thirty-one examples of
small deletions (2-49 bases) were recorded. Most ofthese dele-
tions were flanked by 2-5 base direct repeat sequences. More
than 150 mutants displaying splicing aberrations have been iden-
tified. These include examples of single, multiple, and partial ex-
on loss and involve all exons except exon 1. (Exon 4 [28%] and
8 [30%] are most frequent.) Ten of fourteen sequenced exon loss
mutants displayed base substitutions at the splice acceptor or
donor region of the missing exon. The remaining mutations most
likely contain point mutations or small deletions within other in-
tron sequences involved in splicing.
Considering only the in vivo mutations (46 Lesch-Nyhan ger-
minal, 51 normal adult somatic, 86 exposed adult somatic),
several hotspots of mutation were observed. In particular, four
basespair sites have been observed to be mutated in all groups.
However, an additional 132 sites have been recorded with only
a single observation per site. This suggests that there are many
more sites inhprt that routinely mutate in viw (perhaps 100-200
additional sites), although the total number of in vivo mutations
analyzed to date is not large enough to have observed them all.
HLA. Approximately 30% of the background mutations in
adults result from total deletions of the gene as detected on
Southern blots (14). At HLA also, some deletions appear to be
quite large, as demonstrated by the associated phenotypic loss of
the HLA-B antigen coded by the allele in "cis" with the deleted
HLA-A allele. Thus, deletions of> 1000kb are seen. More im-
portantly, recent molecular analyses of in vivo-derived HLA loss
mutants show that approximately 30% also arise from mitotic
recombination (15). Therefore, this important class of mutations
can be recognized at the molecular level. At present, there are no
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published sequence data on in vivo HLA mutations defining the
nature of point mutations at this locus.
Somatic Cell Gene Mutations Induced
in Vivo by Environmental Mutagens
The utility of the assays of in vivo somatic mutation for en-
vironmental monitoring is being assessed by definirg their ability
to detect human exposures to model mutagens, e.g., smoking,
cytotoxic chemotherapy and ionizing radiations, or to genotox-
ic agents in well-defined accidents. Most investigations have
shown clear increases in VforMfvalues in exposed individuals.
Effects of Smoking
Definite increases in in vivo hprt Mf values due to smoking
have been reported by several laboratories (5,16-18). In fact, this
increase was greater than 50% in smokers compared to non-
smokers in one study (16). Other studies, however, have reported
weaker or no effects (19,20). Smoking also results in somewhat
higher GPA Vfvalues than for nonsmokers, but, in most studies,
this increase does not achieve statistical significance (3). Pre-
liminary results in ethylene oxide workers and ataxia telangiec-
tasia and xeroderma pigmentosum heterozygotes suggest that in
smokers the frequency ofHbS variant cells is doubled as com-
pared to nonsmokers (21).
Exposure to Cytotoxic Chemotherapeutic Agents
Most studies ofcancer patients undergoing chemotherapy have
shown clear increases in hprtT-cell Mfvalues (22-24). A similar
increase has been seen for GPA mutations (25). However, a re-
cent study of 31 breast cancer patients receiving either chemo-
therapy, radiotherapy, or both reported no significant increase in
hprt Mf attributable to chemotherapy (26). The significant in-
creases seen in treated patients could be accounted for solely by
radiotherapy. Two of the agents received by these patients,
cyclophosphamide and adriamycin have been implicated as
mutagens in other studies of in vivo somatic mutation (25,27).
We have recently completed a similar study ofwomen with
breast cancer receiving potentially mutagenic therapies, and we
obtained quite different results (20,28). All patients in our study
had surgery with curative intent; subsequent therapy was in the
adjuvant mode. Group 1 patients had no therapy beyond surgery,
or had hormonal therapy, group 2 patients had local radiotherapy
with or without hormonal therapy, and group 3 patients had
chemotherapy with or without radiotherapy and/or hormones.
The first blood sample was obtained after surgery but before the
onset ofadjuvant therapy; subsequent samples were obtained at
6-month intervals. Women presenting with noncancerous breast
masses served as controls.
In contrast to the study noted above, there was a significant in-
crease inmeanMfat6 months inwomen receivingchemothera-
py (18.2 ± 1.7 x 10-6) comparedtoprechemotherapy (11.1 ± 1.4
x 10 -6). A more modest increase inmeanpost-treatmentMfwas
seen after local radiotherapy, but neither this, nor the slight in-
crease in the group patients, reached statistical significance.
Following chemotherapy, hprt Mf values returned toward
baseline, but remained somewhat elevated.
Comparison of the two hprt studies ofbreast cancer patients
reveals factors that may be ofimportance in interpreting in vivo
mutagenicity studies. In the study showing no significant
chemotherapy effects, the time ofassay relative to chemotherapy
was variable. Timing is probably extremely important for op-
timally detecting hprt mutant T-cells in peripheral blood. Sam-
pling long after an exposure may well underestimate hprt muta-
tion induction. Also, some ofthis difference was due to the kind
of chemotherapy received, with fluorouracil and methotrexate
producing little mutagenicity. In addition, individual factors may
also be ofimportance, such as serum folate levels in the deficien-
cy range, which were particularly common in the women who
had the mostmarked Mfelevatiqns after chemotherapy. At pre-
sent, there are no published reports ofmolecular analyses ofhprt
mutations following a specific cancer chemotherapy or other
form of in vio chemical mutagenesis. However, several studies
are in progress (see above for summary ofcurrent sequence in-
formation). The expectation is that different chemical mutagens
will be shown to induce different molecular spectra ofmutations,
thereby producing signatures for specific recognition.
Exposures to Ioniing Radiation
hprt. Mfs have been studied in several groups ofhumans ex-
posed to ionizing radiation (24,27,29-32). Induced mean fre-
quencies in exposed individuals have varied from a low of7.5 x
io-9 to a high of 5.5 x 10-6/cGy. This range of almost three
orders ofmagnitude illustrates, in the extreme, the importance
of timing in measuring in vivo-induced hprt mutations in pe-
ripheral blood T-cells. The rate of induction determined in ser-
vivors of the atomic bomb explosion is 7.5 x 10-' and was
determined almost 45 years after the mutants were induced (32).
Eliminating this study reveals the range ofhprt mutant induction
by ionizing radiation to be approximately 1-5 x 10-6/cGy for
high-dose, low linear energy transfer irradiations.
The GPA assay was also used in studies of atomic bomb sur-
vivors 45 years after the event (33,34). These studies revealed an
increment of approximately 0.4 x 10-6 induced GPA mutant
RBCs/cGy, even at this late date, with a good deal of interin-
dividual variability. Such results in RBCs are in accord with stem
cell mutations, discussed above.
In an effort to better define the in vivo mutagenic effects of
ionizing radiation, our laboratory has determined hprt Mfs in
cancer patients exposed to an internal y-emitting radionuclide
(131') (radioimmunotherapy [RT) producing totalbody irradia-
tion in an exponentially decaying dose (35,36). We determined
Mfvalues in 13 patients before and 36 patients after treatment.
The post-treatment group included 11 samples obtained 2 months
after a first treatment of62-104 cGy, 18 samples 2 months after
the last of a series of multiple treatments (cumulative total of
128-669 cGy), and 7 samples obtained 10-48 months after the
last of multiple treatments (cumulative total of 128-324 cGy).
Based on either the dose of the first single treatment or the last
of the multiple treatments, a dose-response relationship of
0.9-1.1 x 10-6 mutants/cCy was seen. Based on the total
cumulative exposure, this induction feil to 0.2-0.3 x 10' in the
2-month samples, and to 0.09 x 10-6 in the 10-48-month
samples. (This dose response compares with a value of 0.2 x
10-6 mutants/cGy in T-cells acutely irradiated in vitro.) These
time-dependent declines in the in viw Mf point again to the
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Table 3. Gross structural alteration in in viwv hprt mutations.
Change on Southern blot
Total Partial Single New fragment No % Gross
Subject deletion deletion breakpoint only change Total alteration
Normals 9 (22%) 20 (49%) 9 (22%) 3 (7%) 246a 287b 14.2
pre-RIT 3 (15%) 10(50%) 6 (30%) 1 (5%) 98 118 16.9
post-RIT 37 (41%) 27 (30%) 22 (24%) 4(4%) 145 235 38.3
RIT, radioimmunotherapy.
aIndependent mutations without visible alteration on Southern blot.
bTotal independent mutations studied for the group.
importance of sampling time in human in vivo mutagenicity
studies. Nonetheless, in vivo exposures to whole-body ionizing
radiation clearly result in dose-dependent increases in hprt Mf.
Ionizing radiation is known to induce gross structural altera-
tions in hprt and other recorder genes in cultured human and
other mammalian cells. Bradley et al. (8) found an increased fre-
quency of mutants with gross structual alterations on Southern
blots in patients who had received radionuclides for diagnostic
purposes (33%) as compared to patients before receiving ra-
dionuclides (13 %). In atomic bomb survivors, the frequencies of
mutations showing gross structural alterations at hprt were essen-
tially the same in individuals exposed to radiation from the bomb
compared to nonexposed controls (9); however, as noted, the
study was conducted almost 45 years after the exposure.
Our laboratory recently completed an analysis of241 indepen-
dent in vivo hprt mutational events, isolated from 19 RIT patients
(35,36). The hprt molecular lesions in these mutations were
compared with the hprt molecular lesions in 118 in vivo mutations
from 4 cancer patients before their therapy and in 287 back-
ground in vivo mutations in normal young males (Table 3). The
mutations from post-RIT patients showed clearly greater fre-
quencies ofgross structural alterations than those from pre-RIT
or normal individuals. The latter two frequencies are quite
similar, suggesting that cancer per se does not produce this sort
of damage at hprt.
This difference in the kinds of in vivo hprt mutations after
ionizing radiation, compared to in vivo mutations before ex-
posure or in normals, extends to the sizes of the molecular le-
sions. Post-RIT patients have much higher frequencies of total
gene deletions. Therefore, not only is the frequency of in vivo
mutations with gross structural alterations increased after ioniz-
ing radiation exposures, the percentage oflesions with large dele-
tions is increased. In individuals from whom 10 or more in-
dependent in vivo hprt mutations could be analyzed, the correla-
tion between fraction of mutations with gross structural altera-
tions and cumulative radiation dose was 0.79 (r = 0.82, r2 =
0.67 for the linear regression). Therefore, in our studies, 67% of
the variability in fraction of in vivo mutations with gross struc-
tual alterations could be explained by ionizing radiation
exposure.
Taken in toto, the data for in vivo hprt T-cell mutations indicate
that ionizing radiation produces deletions and that deletions, par-
ticularly large deletions, characterize the in vivo mutational spec-
trum for this sort ofhuman mutagen exposure. There may also
be a characteristic point mutational spectrum for in vivo hprt
mutations resulting from ionizing radiation exposure. Sequence
studies are in progress.
Occupational or Residential Mutagen Exposures
There are several published reports ofhuman monitoring, us-
ing the hprt cloning assay, for in vivo effects of occupational or
residential chemical or radiation mutagen exposures
(18,19,37-41). For ionizing radiation, mutation induction appears
to be more efficient for low-dose irradiations, being in the range
of 10- induced mutants/cGy in some studies also (39-41). Oc-
cupational exposures to chemical mutagens (e.g., chemotherapy
nurses) resulted in elevations in Mf (18,37), but not when special
precautions were taken (19).
A recent, well-controlled study ofthe association between hprt
Mfin peripheral blood T-cells and household radon concentra-
tions deserves special mention (38). A significant association
was found between the log Mf and radon concentration. The
doubling dose for Mf, estimated from two separate meas-
urements ofhousehold radon concentrations, was 330 Bq/m3 and
210 Bq/m3, respectively. The authors caution that these data must
be regarded as preliminary and that further, more extensive
studies should be done. Molecular studies of these in vivo hprt
mutations are clearly indicated.
Relevance of Mutation in Somatic
Recorder Genes to Cancer
Several features of somatic cell gene mutation discovered thus
far suggest that the recorder genes being studied serve as sur-
rogates for cancer-causing mutations. First, considered in detail,
is the finding that exposures to genotoxic carcinogens result in
elevations in Mf (Vf) and, for ionizing radiation, result in a
characteristic mutational spectrum. Also, two of the recorder
genes being studied, GPA and HLA, permit recognition of
somatic cell recombination and/or gene conversion. These muta-
tional events are known to be important in the genesis ofcancer.
Two additional features indicating relevance to cancer are
demonstrated by studies of hprt.
Analysis ofbackground hprt mutations in normal individuals
indicates that cell division in vivo is an important mutagenic in-
fluence. Several individuals with in vivo clonal amplifications of
T-cells, detected by concomitant studies of TcR genes, have
shown that the hprt mutations are occurring within the expanding
clone (1,2). One individual with a massive clonal expansion has
shown four different mutational events in this single clone. This
suggests that unremitting cell division can create space for se-
quential gene mutations to accumulate in descendants ofthe same
cell. Perhaps the spontaneous mutations resulting from copy er-
ror in cells stimulated to continual division have an important
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role in the genesis of spontaneous human cancers, with the role
of environmental agents being to induce such cell division.
A more recent observation comes from studies of fetal in vivo
hprt mutations, as reflected by studies of placental cord blood.
Background Mfvalues for newborns, determined in this way, are
approximately 10-fold lower than for adults, i.e., 5 x 10-7
(16,42,43). Molecular analyses of these fetal mutations show that
they frequently arise in prethymic cells and that their mutational
spectrum is characterized by specific deletions ofhprt exons 2
and 3, with deletion breakpoints giving rise to these deletions
ocurring at a single site in intron 1 and at several sites in intron
3 (45). The sites have in common all or an important portion of
the consensus heptamer [CAC(T/A)GTG] for the VDJ recom-
binase that mediates cleavage ofthe TcR genes during thymic on-
togeny (46). Other hallmarks of a VDJ recombinase-mediated
cleavage event characterize the junctional regions of the hprt
deletions. Therefore, an illegitimate recombinase-mediated event
can occur in the hprt gene which, when operative, accounts for
30% or more ofthe background mutations. A similar event has
been shown to occur in a growth factor gene in 25% of acute T-
cell leukemias (47,48), where it may be pathogenic, and as an in-
termediate to several ofthe chromosomal translocations seen in
B-cell lymphomas (49). Thus, a mutagenic event that may be
termed developmental mutagenesis has been uncovered by
studies of in vivo hprt mutations in humans. Further studies
should reveal its relevance to human cancer.
Conclusions
The status of in vivo somatic cell mutations as biomarkers for
human studies has changed a good deal in recent years. Several
markers of mutation are now available, and more are certain to
come. Also, insights have been obtained that give a somewhat
different picture than that derived from studies of in vitro muta-
tions. These insights have provided an understanding of the
biology ofthe different in vwvo mutagenicity assays in use. Results
of human monitoring studies can now be interpreted in light of
this biological understanding. The use ofthese assays in basic in-
vestigations of somatic cell mutation, and its role in human
disease, is great.
The role of human in vivo somatic cell mutations as bio-
markers for genotoxic carcinogen exposures is also being
developed. Studies reviewed here indicate that mutations are in-
duced by exposures to these agents and may be quite sensitive in-
dicators of such exposures. The markers certainly are useful as
population indicators of genotoxicity. Also, the ongoing
molecular studies of in vivo-induced mutants may reveal char-
acteristic mutational spectra that will allow "diagnosis" of
specific deleterious agents. It may even be possible eventually to
make individual health risk assessments following genotoxic ex-
posures, although the potential for this is currently unexplored.
A major goal in continuing studies ofin vivo somatic cell muta-
tion in humans remains the development of methods for
mutagenicity monitoring that will result in health benefits to the
individuals studied.
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